Milestone Pharmaceuticals Inc
MIST1.496USD
+0.066+4.62%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
79.98MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Milestone Pharmaceuticals Inc Unternehmen
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Unternehmensinformationen
BörsenkürzelMIST
Name des UnternehmensMilestone Pharmaceuticals Inc
IPO-datumMay 09, 2019
CEOMr. Joseph Oliveto
Anzahl der mitarbeiter33
WertpapierartOrdinary Share
GeschäftsjahresendeMay 09
Addresse420-1111 boul. Dr.-Frederik-Philips
StadtMONTREAL
BörseNASDAQ Global Select Consolidated
LandCanada
PostleitzahlH4M 2X6
Telefon15143360444
Websitehttps://www.milestonepharma.com
BörsenkürzelMIST
IPO-datumMay 09, 2019
CEOMr. Joseph Oliveto
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Independent Director
Independent Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 26
Aktualisiert: Sat, Jul 26
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Trails Edge Capital Partners LP
6.28%
Oliveto (Joseph Gerard)
2.95%
RTW Investments L.P.
2.95%
Propel Bio Management, LLC
1.71%
Alta Fundamental Advisers LLC
1.68%
Other
84.43%
Aktionäre
Aktionäre
Anteil
Trails Edge Capital Partners LP
6.28%
Oliveto (Joseph Gerard)
2.95%
RTW Investments L.P.
2.95%
Propel Bio Management, LLC
1.71%
Alta Fundamental Advisers LLC
1.68%
Other
84.43%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
9.84%
Individual Investor
3.61%
Investment Advisor/Hedge Fund
3.37%
Hedge Fund
2.90%
Research Firm
2.38%
Venture Capital
1.77%
Bank and Trust
0.03%
Other
76.11%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
98
14.43M
18.73%
-14.88M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
2023Q2
108
21.35M
63.87%
-11.78M
2023Q1
110
22.19M
66.58%
-11.98M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Oliveto (Joseph Gerard)
2.44M
4.57%
+2.16M
+756.94%
Apr 15, 2025
RTW Investments L.P.
2.51M
4.69%
--
--
Mar 31, 2025
Propel Bio Management, LLC
1.45M
2.71%
+1.25M
+625.78%
Mar 31, 2025
Alta Fundamental Advisers LLC
1.43M
2.67%
-1.23M
-46.31%
Mar 31, 2025
BML Capital Management LLC
1.14M
2.13%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
965.92K
1.81%
-320.62K
-24.92%
Mar 31, 2025
Simplify Asset Management Inc
850.00K
1.59%
+850.00K
--
Mar 31, 2025
TD Securities, Inc.
750.00K
1.4%
--
--
Mar 31, 2025
Lion Point Capital, L.P.
548.81K
1.03%
-477.00K
-46.50%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Simplify Propel Opportunities ETF
2.84%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
Anteil2.84%
SPDR S&P International Small Cap ETF
Anteil0.01%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
